Valeant Pharmaceuticals International (VRX) : During the past 4 weeks, traders have been relatively bearish on Valeant Pharmaceuticals International (VRX), hence the stock is down -3.12% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.3% relative to the S&P 500. The 4-week change in the price of the stock is -5.08% and the stock has fallen -2.78% in the past 1 week.
The stock has recorded a 20-day Moving Average of 7.36% and the 50-Day Moving Average is 4.73%.The 200 Day SMA reached 45.13% Valeant Pharmaceuticals International, Inc. is up 23.77% in the last 3-month period. Year-to-Date the stock performance stands at -73.16%.
Valeant Pharmaceuticals International (VRX) : The most positive equity analysts on Valeant Pharmaceuticals International (VRX) expects the shares to touch $81, whereas, the least positive believes that the stock will trade at $22 in the short term. The company is covered by 11 Wall Street Brokerage Firms. The average price target for shares are $42 with an expected fluctuation of $15.8 from the mean.
Company shares have received an average consensus rating of Hold for the current week Valeant Pharmaceuticals International (NYSE:VRX): stock was range-bound between the intraday low of $26.77 and the intraday high of $27.45 after having opened at $27.24 on Fridays session. The stock finally closed in the red at $27.24, a loss of -0.33%. The stock remained in the red for the whole trading day. The total traded volume was 10,477,284 shares. The stock failed to cross $27.45 in Fridays trading. The stocks closing price on Thursday was $27.28.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.